Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model
| Autor: | Alireza Partoazar, Mousa Sahebgharani, Sakineh Alijanpour, Nasrin Takzaree, Partow Mirzaee Saffari, Farshid Noorbakhsh, Shahroo Etemad-Moghadam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_treatment Inflammation Phosphatidylserines Disease Pharmacology Hippocampus 030226 pharmacology & pharmacy Streptozocin General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Alzheimer Disease Memory medicine Animals Memory impairment Rats Wistar General Pharmacology Toxicology and Pharmaceutics Neuroinflammation Memory Disorders business.industry General Medicine Phosphatidylserine Streptozotocin Metformin Rats Disease Models Animal 030104 developmental biology Cytokine chemistry Liposomes Cytokines Nanoparticles medicine.symptom business medicine.drug |
| Zdroj: | Life Sciences. 255:117861 |
| ISSN: | 0024-3205 |
| Popis: | Alzheimer's disease (AD) is closely associated with neuroinflammation development in the brain. Co-delivery of metformin (MET) with phosphatidylserine liposomes neuroprotectant may be beneficial in ameliorating AD-related symptoms like memory impairment and inflammation. Therefore, we aimed to prepare metformin containing phosphatidylserine nanoliposomes formulation (MET-PSL) and to evaluate its effect on rats subjected to AD. Alzheimer's disease model was induced by bilateral intracerebroventricular injection of streptozotocin (3 mg/kg) into rat brains using the stereotactic technique. MET-PSL, MET, and PSL alone were administered intraperitoneally to AD-induced animals and factors including learning and memory storage in addition to cytokine and tissue inflammatory changes were evaluated after a 22-day experiment period. The learning and memory parameters significantly (P 0.05) improved in AD-rats treated with MET-PSL. Moreover, MET-PSL administration significantly (P 0.05) decreased cytokine levels of IL1-β, TNF-α, and TGF-β in hippocampal tissues of rats with AD. Histological results indicated a considerable reduction in inflammatory and necrotic neural cells along with significantly (P 0.05) increased neurogenesis in MET-PSL treated rats. Furthermore, our results showed that MET-PSL formulation could potentially act better than the free form of MET and PSL alone in the recovery process of rats with AD. In general, our data suggest that combination therapy of metformin loaded phosphatidylserine liposomes may enhance the therapeutic performance in AD patients of a clinical study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect